Long Grove to launch sodium bicarbonate injection
Long Grove Pharmaceuticals is set to introduce Sodium Bicarbonate Injection.
The product is commonly used in critical care settings yet routinely found on the drug shortages list, the company said.
Sodium Bicarbonate Injection is indicated in the treatment of metabolic acidosis from severe renal disease, uncontrolled diabetes and cardiac arrest. It is most frequently used in critical care settings.
[Read more: Long Grove launches premix norepinephrine]
"As we look at the launch of our next pharmaceutical products, our focus is always on the area of greatest need. Sodium Bicarbonate Injection supply is historically unstable, creating a challenging environment for hospitals and the patients they serve," said Peter Karas, chief commercial officer at Long Grove Pharmaceuticals. "We’re excited by the opportunity to help alleviate drug shortages for this product and continue our commitment to ensuring patients have access to the medicine they need.”
[Read more: Long Grove gets FDA OK for generic Radicava]
The company will launch its 8.4% Sodium Bicarbonate Injection, 50 mEq/ 50 ml vials in the second half of 2024.